Regeneron Pharmaceuticals (REGN) Receives New Coverage from Analysts at Credit Suisse Group

Credit Suisse Group began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Monday morning, The Fly reports. The firm issued a neutral rating on the biopharmaceutical company’s stock.

Several other research firms also recently issued reports on REGN. Cantor Fitzgerald reiterated a hold rating and issued a $441.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. BidaskClub downgraded Regeneron Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, April 25th. Oppenheimer boosted their price objective on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an outperform rating in a report on Thursday, February 7th. Jefferies Financial Group cut their price objective on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a hold rating on the stock in a report on Wednesday, April 17th. Finally, Canaccord Genuity reiterated a hold rating and issued a $353.00 price objective (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, May 8th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Hold and an average target price of $404.88.

REGN stock opened at $302.57 on Monday. The company has a current ratio of 4.58, a quick ratio of 3.78 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $33.06 billion, a P/E ratio of 15.28, a PEG ratio of 1.44 and a beta of 1.08. Regeneron Pharmaceuticals has a 12-month low of $291.10 and a 12-month high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79). The firm had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.76 billion. Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. Regeneron Pharmaceuticals’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.67 EPS. On average, research analysts expect that Regeneron Pharmaceuticals will post 18.37 EPS for the current year.

In other news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neil Stahl sold 9,853 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total value of $3,012,456.22. Following the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The disclosure for this sale can be found here. Insiders have sold a total of 141,968 shares of company stock valued at $57,360,056 over the last three months. 11.84% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.8% in the 1st quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 25 shares during the period. Cornerstone Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 3.7% during the 1st quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 30 shares during the last quarter. Comprehensive Portfolio Management LLC raised its stake in Regeneron Pharmaceuticals by 4.1% during the 1st quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 33 shares during the last quarter. Kaizen Advisory LLC raised its stake in Regeneron Pharmaceuticals by 21.2% during the 4th quarter. Kaizen Advisory LLC now owns 200 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 35 shares during the last quarter. Finally, OppenheimerFunds Inc. raised its stake in Regeneron Pharmaceuticals by 2.6% during the 1st quarter. OppenheimerFunds Inc. now owns 1,465 shares of the biopharmaceutical company’s stock valued at $602,000 after acquiring an additional 37 shares during the last quarter. 67.63% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: 52-Week High/Low

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.